- Home
- PCYO vs LUNG Comparison
PCYO vs LUNG Comparison
Compare PCYO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- LUNG
- Stock Information
- Founded
- PCYO 1976
- LUNG 1995
- Country
- PCYO United States
- LUNG United States
- Employees
- PCYO N/A
- LUNG N/A
- Industry
- PCYO Water Supply
- LUNG Industrial Specialties
- Sector
- PCYO Utilities
- LUNG Health Care
- Exchange
- PCYO Nasdaq
- LUNG Nasdaq
- Market Cap
- PCYO 248.0M
- LUNG 124.0M
- IPO Year
- PCYO N/A
- LUNG 2020
- Fundamental
- Price
- PCYO $11.09
- LUNG $2.78
- Analyst Decision
- PCYO
- LUNG Buy
- Analyst Count
- PCYO 0
- LUNG 6
- Target Price
- PCYO N/A
- LUNG $11.53
- AVG Volume (30 Days)
- PCYO 40.5K
- LUNG 311.3K
- Earning Date
- PCYO 07-09-2025
- LUNG 07-30-2025
- Dividend Yield
- PCYO N/A
- LUNG N/A
- EPS Growth
- PCYO 118.08
- LUNG N/A
- EPS
- PCYO 0.59
- LUNG N/A
- Revenue
- PCYO $29,911,000.00
- LUNG $87,473,000.00
- Revenue This Year
- PCYO N/A
- LUNG $18.02
- Revenue Next Year
- PCYO N/A
- LUNG $18.17
- P/E Ratio
- PCYO $18.84
- LUNG N/A
- Revenue Growth
- PCYO 58.85
- LUNG 19.84
- 52 Week Low
- PCYO $9.10
- LUNG $2.50
- 52 Week High
- PCYO $14.63
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- PCYO 63.99
- LUNG 41.83
- Support Level
- PCYO $10.16
- LUNG $2.52
- Resistance Level
- PCYO $11.16
- LUNG $2.84
- Average True Range (ATR)
- PCYO 0.33
- LUNG 0.16
- MACD
- PCYO 0.09
- LUNG 0.04
- Stochastic Oscillator
- PCYO 93.97
- LUNG 46.36
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.